Alamar Biosciences, alongside the Alzheimer’s Disease Data Initiative and Gates Ventures, launched a large-scale international collaboration to generate a comprehensive plasma proteomic dataset profiling Alzheimer's disease and dementias. Utilizing ultra-sensitive proteomic panels, this project aims to accelerate biomarker discovery and therapeutic insights by integrating protein profiles with clinical outcomes across multiple countries.